Cargando…

High activity of sequential low dose chemo-modulating Temozolomide in combination with Fotemustine in metastatic melanoma. A feasibility study

Detalles Bibliográficos
Autores principales:	Guida, Michele, Cramarossa, Antonio, Fistola, Ettore, Porcelli, Mariangela, Giudice, Giuseppe, Lubello, Katia, Colucci, Giuseppe
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2010
Materias:	Protocol
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2992498/ https://www.ncbi.nlm.nih.gov/pubmed/21067582 http://dx.doi.org/10.1186/1479-5876-8-115

Ejemplares similares

The search for a melanoma-tailored chemotherapy in the new era of personalized therapy: a phase II study of chemo-modulating temozolomide followed by fotemustine and a cooperative study of GOIM (Gruppo Oncologico Italia Meridionale)
por: Guida, Michele, et al.
Publicado: (2018)

Sequential administration of varying doses of dacarbazine and fotemustine in advanced malignant melanoma.
por: Lee, S. M., et al.
Publicado: (1993)

B-Raf inhibitor vemurafenib in combination with temozolomide and fotemustine in the killing response of malignant melanoma cells
por: Roos, Wynand P., et al.
Publicado: (2014)

Treatment of disseminated ocular melanoma with sequential fotemustine, interferon α, and interleukin 2
por: Becker, J C, et al.
Publicado: (2002)

High-dose fotemustine in temozolomide-pretreated glioblastoma multiforme patients: A phase I/II trial
por: Marinelli, Alfredo, et al.
Publicado: (2018)

A new schedule of fotemustine in temozolomide-pretreated patients with relapsing glioblastoma
por: Addeo, Raffaele, et al.
Publicado: (2010)

Erratum to: A new schedule of fotemustine in temozolomide-pretreated patients with relapsing glioblastoma
por: Addeo, Raffaele, et al.
Publicado: (2010)

Temozolomide- and fotemustine-induced apoptosis in human malignant melanoma cells: response related to MGMT, MMR, DSBs, and p53
por: Naumann, S C, et al.
Publicado: (2009)

Upfront Bevacizumab and Temozolomide or Fotemustine before Radiotherapy for Patients with Glioblastoma and Severe Neurological Impairment at Diagnosis
por: Bihan, Celina, et al.
Publicado: (2012)

Effects of fotemustine or dacarbasine on a melanoma cell line pretreated with therapeutic proton irradiation
por: Ristić-Fira, Aleksandra M, et al.
Publicado: (2009)

Temozolomide for the treatment of metastatic melanoma
por: Quirbt, I., et al.
Publicado: (2007)

Immune correlates of metastatic melanoma patients treated with ipilimumab in combination with fotemustine in the phase II NIBIT-M1 study
por: Maccalli, Cristina, et al.
Publicado: (2013)

Phase III randomized study of fotemustine and dacarbazine versus dacarbazine with or without interferon-α in advanced malignant melanoma
por: Daponte, Antonio, et al.
Publicado: (2013)

Combined vemurafenib and fotemustine in patients with BRAF V600 melanoma progressing on vemurafenib
por: Queirolo, Paola, et al.
Publicado: (2016)

Treatment of resistant metastatic melanoma using sequential epigenetic therapy (decitabine and panobinostat) combined with chemotherapy (temozolomide)
por: Xia, Chang, et al.
Publicado: (2014)

Formation and loss of O6-methyldeoxyguanosine in human leucocyte DNA following sequential DTIC and fotemustine chemotherapy.
por: Lee, S. M., et al.
Publicado: (1994)

An Overview of Fotemustine in High-Grade Gliomas: From Single Agent to Association with Bevacizumab
por: Lombardi, Giuseppe, et al.
Publicado: (2014)

The Combination of Carmustine Wafers and Fotemustine in Recurrent Glioblastoma Patients: A Monoinstitutional Experience
por: Lombardi, Giuseppe, et al.
Publicado: (2014)

Survival with dacarbazine and fotemustine in newly diagnosed glioblastoma multiforme
por: Fazeny-Dörner, B, et al.
Publicado: (2003)

Regulation of Inflammatory and Proliferative Pathways by Fotemustine and Dexamethasone in Endometriosis
por: Genovese, Tiziana, et al.
Publicado: (2021)

Successful administration of sequential TVEC and pembrolizumab followed by Temozolomide in immunotherapy refractory intracranial metastatic melanoma with acquired B2M mutation
por: Khaddour, Karam, et al.
Publicado: (2020)

Lymphocyte function and response to chemo-immunotherapy in patients with metastatic melanoma.
por: Thatcher, N., et al.
Publicado: (1977)

Complications of sequential immunotherapy in metastatic melanoma
por: Bufalino, Shams, et al.
Publicado: (2015)

Activity and Safety of Bevacizumab Plus Fotemustine for Recurrent Malignant Gliomas
por: Vaccaro, V., et al.
Publicado: (2014)

Biweekly fotemustine schedule for recurrent glioblastoma in the elderly: activity and toxicity assessment of a multicenter study
por: Addeo, Raffaele, et al.
Publicado: (2019)

Addendum: Successful administration of sequential TVEC and pembrolizumab followed by Temozolomide in immunotherapy refractory intracranial metastatic melanoma with acquired B2M mutation
por: Khaddour, Karam, et al.
Publicado: (2023)

Celecoxib reverses the glioblastoma chemo-resistance to temozolomide through mitochondrial metabolism
por: Yin, Delong, et al.
Publicado: (2021)

Efficacy and safety of second-line fotemustine in elderly patients with recurrent glioblastoma
por: Santoni, Matteo, et al.
Publicado: (2013)

Fotemustine: A Third-Generation Nitrosourea for the Treatment of Recurrent Malignant Gliomas
por: Beauchesne, Patrick
Publicado: (2012)

Fotemustine as second-line treatment for recurrent or progressive glioblastoma after concomitant and/or adjuvant temozolomide: a phase II trial of Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO)
por: Brandes, Alba A., et al.
Publicado: (2009)

Central nervous system failure in melanoma patients: results of a randomised, multicentre phase 3 study of temozolomide- and dacarbazine- based regimens
por: Chiarion-Sileni, V, et al.
Publicado: (2011)

Barasertib: a novel approach for the treatment of metastatic melanoma
por: Azzariti, Amalia, et al.
Publicado: (2014)

Efficacy and safety of the third-generation chloroethylnitrosourea fotemustine for the treatment of chemorefractory T-cell lymphomas
por: Corazzelli, Gaetano, et al.
Publicado: (2011)

Retrospective Analysis of Bevacizumab in Combination with Fotemustine in Chinese Patients with Recurrent Glioblastoma Multiforme
por: Liu, Zhiguang, et al.
Publicado: (2015)

Tomatine Displays Antitumor Potential in In Vitro Models of Metastatic Melanoma
por: Serratì, Simona, et al.
Publicado: (2020)

Short Interfering RNA Directed against the SLUG Gene Increases Cell Death Induction in Human Melanoma Cell Lines Exposed to Cisplatin and Fotemustine
por: Vannini, Ivan, et al.
Publicado: (2007)

Ternary cocktail nanoparticles for sequential chemo-photodynamic therapy
por: Fan, Li, et al.
Publicado: (2017)

A Phase I Study of High-Dose Calcitriol in Combination with Temozolomide for Patients with Metastatic Melanoma
por: Pettijohn, Erin, et al.
Publicado: (2014)

Therapeutic Responses to Combination Nivolumab and Temozolomide as Salvage Therapy for Metastatic Melanoma: A Case Series
por: Goodman, Rachel S, et al.
Publicado: (2023)

The relevance of BRAF G469A mutation in determining the response to therapy in metastatic melanoma
por: Porcelli, Letizia, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_pftco33gdrck0ejch81ks8ccrg